PGN 0052

Drug Profile

PGN 0052

Alternative Names: PGN 52; PGN0052

Latest Information Update: 13 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmagene
  • Class Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 09 Nov 2005 Phase-II clinical trials in Cystic fibrosis in United Kingdom (IV-infusion)
  • 26 May 2005 Suspended - Preclinical for Asthma in United Kingdom (IV)
  • 26 May 2005 Suspended - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top